Biogaia AB
STO:BIOG B

Watchlist Manager
Biogaia AB Logo
Biogaia AB
STO:BIOG B
Watchlist
Price: 110.2 SEK 0.64% Market Closed
Market Cap: 11.1B SEK
Have any thoughts about
Biogaia AB?
Write Note

Net Margin
Biogaia AB

24.9%
Current
29%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.9%
=
Net Income
336.8m
/
Revenue
1.4B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Biogaia AB
STO:BIOG B
11.1B SEK
25%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country SE
Market Cap 11.1B SEK
Net Margin
25%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.9B USD
Net Margin
9%
Country US
Market Cap 140.6B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 103.9B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 77.8B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Biogaia AB
Glance View

Market Cap
11.1B SEK
Industry
Biotechnology

BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.

BIOG B Intrinsic Value
113.42 SEK
Undervaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.9%
=
Net Income
336.8m
/
Revenue
1.4B
What is the Net Margin of Biogaia AB?

Based on Biogaia AB's most recent financial statements, the company has Net Margin of 24.9%.